Literature DB >> 15917956

Serum laminin, type IV collagen and hyaluronan as fibrosis markers in non-alcoholic fatty liver disease.

V N Dos Santos1, M M B Leite-Mór, M Kondo, J R Martins, H Nader, V P Lanzoni, E R Parise.   

Abstract

Hepatic fibrosis in patients with non-alcoholic fatty liver disease is associated with progression of the disease. In the present study, we analyzed the discriminative ability of serum laminin, type IV collagen and hyaluronan levels to predict the presence of fibrosis in these patients. In this preliminary report, we studied 30 overweight patients divided into two groups according to the absence (group I, N = 19) or presence (group II, N = 11) of fibrosis in a liver biopsy. Triglycerides, aspartate aminotransferase, alanine aminotransferase, gamma-glutamyltranspeptidade, hyaluronan (noncompetitive fluoroassay), type IV collagen, and laminin (ELISA) were determined. Group II presented significantly higher mean laminin, hyaluronan, type IV collagen, and aspartate aminotransferase values, which were due to the correlation between these parameters and the stage of fibrosis in the biopsy (Spearman's correlation coefficient, rS = 0.65, 0.62, 0.53, and 0.49, respectively). Analysis of the ROC curve showed that laminin values >282 ng/ml were those with the best diagnostic performance, with 87% accuracy. Association of laminin with type IV collagen showed improvement in the positive predictive value (100%), but with reduction in diagnostic sensitivity (64%). When compared with the criteria of Ratziu et al. for the diagnosis of septal fibrosis, laminin values presented a better diagnostic accuracy (83 vs 70%). Determination of extracellular matrix components in serum, especially of laminin, may identify patients with non-alcoholic fatty liver disease and fibrosis and these components may be used as indicators for liver biopsy in these patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15917956     DOI: 10.1590/s0100-879x2005000500012

Source DB:  PubMed          Journal:  Braz J Med Biol Res        ISSN: 0100-879X            Impact factor:   2.590


  31 in total

Review 1.  Proteomic and genomic studies of non-alcoholic fatty liver disease--clues in the pathogenesis.

Authors:  Jun Wei Lim; John Dillon; Michael Miller
Journal:  World J Gastroenterol       Date:  2014-07-14       Impact factor: 5.742

2.  Non-invasive Diagnosis of Fibrosis in Non-alcoholic Fatty Liver Disease.

Authors:  Anil Arora; Praveen Sharma
Journal:  J Clin Exp Hepatol       Date:  2012-07-21

Review 3.  Non invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy.

Authors:  Giada Sebastiani; Alfredo Alberti
Journal:  World J Gastroenterol       Date:  2006-06-21       Impact factor: 5.742

Review 4.  Can NASH be diagnosed, graded, and staged noninvasively?

Authors:  Garfield A Grandison; Paul Angulo
Journal:  Clin Liver Dis       Date:  2012-06-26       Impact factor: 6.126

5.  Schistosomiasis mansoni: ultrasound-evaluated hepatic fibrosis and serum concentrations of hyaluronic acid.

Authors:  C C Silva; A L Domingues; E P Lopes; C N Morais; R B Santos; C F Luna; H B Nader; J R Martins
Journal:  Ann Trop Med Parasitol       Date:  2011-04

6.  Peroxiredoxin 2: a potential biomarker for early diagnosis of hepatitis B virus related liver fibrosis identified by proteomic analysis of the plasma.

Authors:  Ye Lu; Jie Liu; Chengzhao Lin; Haijian Wang; Ying Jiang; Jiyao Wang; Pengyuan Yang; Fuchu He
Journal:  BMC Gastroenterol       Date:  2010-10-13       Impact factor: 3.067

7.  Rat and human HARE/stabilin-2 are clearance receptors for high- and low-molecular-weight heparins.

Authors:  Edward N Harris; Bruce A Baggenstoss; Paul H Weigel
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-04-09       Impact factor: 4.052

Review 8.  Is there a place for serum laminin determination in patients with liver disease and cancer?

Authors:  Heitor Rosa; Edison Roberto Parise
Journal:  World J Gastroenterol       Date:  2008-06-21       Impact factor: 5.742

9.  Non-invasive assessment of liver fibrosis in chronic liver diseases: implementation in clinical practice and decisional algorithms.

Authors:  Giada Sebastiani
Journal:  World J Gastroenterol       Date:  2009-05-14       Impact factor: 5.742

Review 10.  Noninvasive evaluation of NAFLD.

Authors:  Laurent Castera; Valérie Vilgrain; Paul Angulo
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-09-24       Impact factor: 46.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.